ATP5MF-PTCD1

Across TCGA pan-cancer cohorts, ATP5MF-PTCD1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ATP5MF-PTCD1 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ATP5MF-PTCD1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP5MF-PTCD1 expression acts as an unfavorable survival marker.

OV and UCEC are the cancer types where ATP5MF-PTCD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.104	0.541	<.001	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ATP5MF-PTCD1–OV (DFS)

Open the OV breakdown →